1. "Solid Tumor Oncology Division"
  2. "Melanoma Disease Management Team"
Formats
  1. Journal Article (507)
  2. Meeting Abstract (347)
  3. Editorial (20)
  4. Review (18)
  5. Book Section (15)
  6. Research Letter (10)
  7. Book Whole (4)
  8. Guidelines (4)
  9. Miscellaneous (4)
  10. Conference Paper (1)
  11. Correspondence (1)
Groups
  1. Department of Medicine (931)
  2. Melanoma Disease Management Team (931)
  3. Solid Tumor Oncology Division (931)
  4. Melanoma and Immunotherapeutics Service (729)
  5. Hematologic Malignancies, Division of (384)
  6. GSK Faculty (380)

More Groups

People
  1. Michael Postow (328)
  2. Alexander Shoushtari (221)
  3. Jedd Wolchok (220)
  4. Govindaswami Ragupathi (144)
  5. Daniel Coit (120)
  6. Philip Livingston (119)

More People

Years
  1. 2024 (10)
  2. 2023 (66)
  3. 2022 (89)
  4. 2021 (91)
  5. 2020 (69)
  6. 2019 (55)

More Years

Publications
  1. Journal of Clinical Oncology (182)
  2. Journal for ImmunoTherapy of Cancer (57)
  3. Clinical Cancer Research (39)
  4. Annals of Oncology (36)
  5. Annals of Surgical Oncology (35)
  6. Cancer Research (33)

More Publications

Publishers
  1. American Society of Clinical Oncology (189)
  2. American Association for Cancer Research (116)
  3. Springer (80)
  4. Biomed Central Ltd (74)
  5. Oxford University Press (62)
  6. Elsevier Inc. (60)

More Publishers

Results (931)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Telomerase reverse transcriptase (TERT) promoter mutations are associated with higher tumor mutational burden and UV mutational signature in melanoma
    Meeting Abstract

    Leinwand, J. C.; Koh, E.; Bartlett, E.; Bello, D.; Brady, M. S.; Harding, J. J.; Morris, L.; Ariyan, C.
    Annals of Surgical Oncology (2024)

    Fulltext@MSK | Save
  • A phase II single arm trial of induction and concurrent vismodegib with curative intent radiation therapy for locally advanced, unresectable basal cell carcinoma of the head and neck
    Meeting Abstract

    Barker, C. A.; Arron, S.; Ho, A.; Algazi, A.; Dunn, L.; Humphries, A.; Hultman, C.; Lian, M.; Knott, P. D.; Yom, S. S.
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: A propensity score-weighted analysis
    Journal Article

    Piulats, J. M.; Watkins, C.; Costa-García, M.; del Carpio, L.; Piperno-Neumann, S.; Rutkowski, P.; Hassel, J. C.; Espinosa, E.; de la Cruz-Merino, L.; Ochsenreither, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Clearance of plasma cell free DNA in metastatic uveal melanoma with radiographic response to immune checkpoint inhibitors
    Journal Article

    Francis, J. H.; Barker, C. A.; Canestraro, J.; Abramson, D. H.; Shoushtari, A. N.
    American Journal of Ophthalmology Case Reports (2024)

    Fulltext@MSK | Save
  • Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer
    Journal Article

    Lumish, M. A.; Walch, H.; Maron, S. B.; Chatila, W.; Kemel, Y.; Maio, A.; Ku, G. Y.; Ilson, D. H.; Won, E.; Li, J.; more...
    JNCI: Journal of the National Cancer Institute (2024)

    Fulltext@MSK | Save
  • Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: A systematic review and meta-analysis
    Review

    Sala, I.; Pagan, E.; Pala, L.; Oriecuia, C.; Musca, M.; Specchia, C.; De Pas, T.; Cortes, J.; Giaccone, G.; Postow, M.; more...
    Frontiers in Immunology (2024)

    Fulltext@MSK | Save
  • Prophylactic radiation therapy versus standard of care for patients with high-risk asymptomatic bone metastases: A multicenter, randomized phase II clinical trial
    Journal Article

    Gillespie, E. F.; Yang, J. C.; Mathis, N. J.; Marine, C. B.; White, C.; Zhang, Z.; Barker, C. A.; Kotecha, R.; McIntosh, A.; Vaynrub, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients
    Journal Article

    Gu, S.; Dusza, S.; Quigley, E.; Haliasos, H.; Markova, A.; Marchetti, M.; Moy, A. P.; Dang, C.; Modi, S.; Lake, D.; more...
    Breast Cancer Research and Treatment (2024)

    Fulltext@MSK | Save
  • Prevalence of enteric infections in patients on immune checkpoint inhibitors and impact on management and outcomes
    Journal Article

    Magahis, P. T.; Satish, D.; Babady, N. E.; Kamboj, M.; Postow, M. A.; Laszkowska, M.; Faleck, D. M.
    The Oncologist (2024)

    Fulltext@MSK | Save
  • The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
    Journal Article

    Hepner, A.; Versluis, J. M.; Wallace, R.; Allayous, C.; Brown, L. J.; Trojaniello, C.; Gerard, C. L.; Jansen, Y. J. L.; Bhave, P.; Neyns, B.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save